Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to TreatmentAversa S.M.L.a · Stragliotto S.a · Marino D.a · Calabrese F.c · Rigotti P.d · Marchini F.d · Gambino A.e · Feltrin G.e · Boso C.b · Canova F.a · Soldà C.a · Mazzarotto R.b · Burra P.f
aDivision of Medical Oncology and bDepartment of Radiotherapy, Istituto Oncologico Veneto, IRCCS, cDepartment of Medical Sciences and Special Therapies, dKidney and Pancreas Transplantation Unit, Department of Medical and Surgical Sciences, eDepartment of Cardiothoracic Sciences and fDepartment of Surgical and Gastroenterological Science, University of Padua, Padua, Italy Acta Haematol 2008;120:36–46 (DOI:10.1159/000155234)
Post-transplant lymphoproliferative disorders (PTLD) is a serious complication after solid organ transplantation. Reduction of immunosuppression (RI) alone is not able to control the disease. We report a prospective analysis of 30 patients with PTLD after heart or kidney transplantation. Only 5 of 30 patients, treated solely with RI, obtained a complete response. Five patients were treated heterogeneously; in the remaining 20, the efficacy and safety of a weekly anthracycline-based chemotherapy were assessed. Sixteen patients obtained a complete remission. One death was related to treatment. With a median follow-up of 36 months, 3-year overall survival was 63.3% and 57% for the entire group and the chemotherapy-treated group, respectively. Moreover, 4 second neoplasms were observed in the chemotherapeutic group. In this study, we demonstrated that most PTLD need other treatment than RI and a weekly regimen is manageable and has a favourable impact on long-term survival.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50